PharmiNews

The Directory of Pharma Companies and News

Eisai

Eisai logo
Eisai Co Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as `giving first thought to patients and their families and to increasing the benefits health care provides,` which we call our human health care (hhc) philosophy. With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realise our hhc philosophy by delivering innovative products in multiple therapeutic areas with high unmet medical needs, including Oncology and Neurology.

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

Category: Pharmaco
Category: Pharmaco

Eisai News

DateNews
2017-05-29Notification of Change to RSS Feed Delivery
2017-05-18EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT 53RD ASCO ANNUAL MEETING RESULTS OF STUDY OF LENVIMA(R) ...
2017-05-10Proposed Changes in Representative Officers
2017-05-03PATENT INFRINGEMENT LITIGATION FOR ANTIEMETIC AGENT ALOXI(R) IN THE UNITED STATES
2017-04-19EISAI ANNOUNCES RESULTS AND CONTINUED SUPPORT OF INITIATIVES FOR ELIMINATION OF LYMPHATIC FILARIASIS5 YEAR ANNIVERSARY O
2017-04-11SPEEDY CARE TO RELIEVE FATIGUE! EISAI TO LAUNCH “CHOCOLA BB(R) GOLD RICH” HIGHEST COMBINATION OF ACTIVE INGREDIENTS IN C...
2017-04-05EISAI AND MEIJI ENTER INTO LICENSING AGREEMENT CONCERNING PARKINSON’S DISEASE DRUG SAFINAMIDE IN JAPAN AND ASIA
2017-04-05EISAI PRESENTS DATA OF MECHANISMS OF ACTION RELATING TO TUMOR IMMUNE RESPONSE REGARDING COMBINATION OF ANTICANCER AGENT ...
2017-04-03EISAI TO LAUNCH SMELL IDENTIFICATION TEST UPSIT SERIES IN JAPAN
2017-03-29ENROLLMENT COMMENCES IN PHASE III CLINICAL STUDY OF EISAI’S BACE INHIBITOR ELENBECESTAT IN EARLY ALZHEIMER’S DISEASE IN ...
2017-03-28GERMAN FEDERAL JOINT COMMITTEE (G-BA) CONFIRMS ADDITIONAL BENEFIT OF ANTICANCER AGENT KISPLYX(R) (LENVATINIB MESYLATE) I...
2017-02-21APPROVAL RECEIVED FOR PAIN TREATMENT LYRICA(R) OD TABLET FORMULATION IN JAPAN
2017-02-16EISAI ENTERS INTO MARKETING AND DISTRIBUTION AGREEMENT WITH ORION CONCERNING PARKINSON’S DISEASE DRUGS IN CHINA
2017-02-02Third Quarter Financial Report for the Fiscal Year Ending March 31, 2017
2017-01-25PHASE III TRIAL OF ANTICANCER AGENT LENVIMA(R) AS FIRST-LINE TREATMENT FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA MEETS P...
2017-01-24EISAI SELECTED FOR EXCELLENCE IN SUSTAINABILITY PERFORMANCE AND INDUSTRY MOVER DISTINCTION BY ROBECOSAM, A LEADING ASSES...
2017-01-24PHASE III TRIAL OF ANTICANCER AGENT LENVIMA(R) AS FIRST-LINE TREATMENT FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA MEETS P...
2017-01-18EISAI TO PARTICIPATE IN ACCESS ACCELERATED,GLOBAL PARTNERSHIP TO ADDRESS RISE OF NON-COMMUNICABLE DISEASES ACCELERATING ...
2017-01-16TRANSFER OF RIGHTS TO INSOMNIA TREATMENT / ANAESTHESIA INDUCTION AGENT FLUNITRAZEPAM IN JAPAN
2017-01-15TRANSFER OF RIGHTS TO INSOMNIA TREATMENT / ANAESTHESIA INDUCTION AGENT FLUNITRAZEPAM IN JAPAN
2017-01-12EISAI TO LAUNCH MEDICATION ADMINISTRATION SUPPORT DEVICE e-OKUSURI-SAN(R) EQUIPPED WITH FUNCTIONS TO SUPPORT LOOKING A
2015-06-26EISAI TO LAUNCH NEW FINE GRANULE FORMULATION OF TACHYARRHYTHMIA TREATMENT TAMBOCOR(R) SUITABLE FOR PEDIATRIC PATIENTS IN...
2015-06-25EUROPEAN COMMISSION APPROVES INDICATION EXPANSION OF EISAI’S ANTIEPILEPTIC AGENT FYCOMPA(R) FOR ADJUNCTIVE TREATMENT OF ...
2015-06-22U.S. FDA APPROVES EISAI’S ANTIEPILEPTIC AGENT FYCOMPA(R) AS ADJUNCTIVE TREATMENT FOR PRIMARY GENERALIZED TONIC-CLONIC SE...
2015-06-10EISAI LAUNCHES ANTICANCER AGENT LENVIMA(R) (LENVATINIB MESYLATE) IN UNITED KINGDOM INDICATED FOR ADVANCED THYROID CANCER...
2015-06-01PHASE II TRIAL RESULTS ON ANTICANCER AGENT LENVIMA(R) IN RENAL CELL CARCINOMA TO BE DETAILED IN ORAL PRESENTATION AT 51S...
2015-06-01EISAI RECEIVES EUROPEAN COMMISSION APPROVAL OF ANTICANCER AGENT LENVIMA(R) FOR TREATMENT OF ADVANCED THYROID CANCER REFR...
2015-05-30ANTICANCER AGENT HALAVEN(R) SHOWS SIGNIFICANT EXTENSION IN OVERALL SURVIVAL IN PHASE III STUDY ON SOFT TISSUE SARCOMA
2015-05-29EISAI SUBMITS APPLICATIONS FOR REEVALUATION OF EFFICACY AND PARTIAL CHANGE TO LABEL OF EGG WHITE LYSOZYME PREPARATION NE...
2015-05-29AbbVie and Eisai Clear All-Case Surveillance Condition for Approval of HUMIRA(R), a Fully Human Anti-TNF-? Mono
2015-05-27EISAI SUBMITS NEW DRUG APPLICATION FOR MECOBALAMIN ULTRA-HIGH DOSE PREPARATION AS TREATMENT FOR AMYOTROPHIC LATERAL SCLE...
2015-05-27EISAI RECIEVES POSITIVE CHMP OPINION ON INDICATION EXPANSION FOR ANTIEPILEPTIC AGENT FYCOMPA(R) (PERAMPANEL) AS ADJUNCTI...
2015-05-21EISAI TO PROMOTE CLINICAL TRIAL DATA DISCLOSURE FOR THE ADVANCEMENT OF SCIENCE AND MEDICINE
2015-05-20EISAI LAUNCHES IN-HOUSE DEVELOPED NOVEL ANTICANCER AGENT LENVIMA(R) (LENVATINIB MESYLATE) AS TREATMENT FOR UNRESECTABLE ...
2015-05-14Annual Financial Report for the Fiscal Year Ended March 31, 2015
2015-05-14Notification Regarding Partial Amendment to the Articles of Incorporation
2015-04-03NIIGATA UNIVERSITY AND EISAI PRESENT RESULTS OF JOINT RESEARCH IN U.S. ACADEMIC JOURNALMEASURING COGNITIVE DECLINE IN PA...
2015-03-30EISAI RECEIVES POSITIVE OPINION FROM EMA'S CHMP ON ANTICANCER AGENT LENVIMA® FOR TREATMENT OF ADVANCED THYROID CANCER RE...
2015-03-26EISAI RECEIVES APPROVAL IN JAPAN FOR ANTICANCER AGENT LENVIMA® (LENVATINIB MESYLATE) AS TREATMENT FOR UNRESECTABLE THYRO...
2015-03-12STATEMENT REGARDING CHANGES TO STRATEGIC PARTNERSHIP WITH EPIZYME, INC. TO DISCOVER, DEVELOP AND COMMERCIALIZE ANTICANCE...
2015-03-05Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK ...
2015-03-03CHINA JSFDA ACCEPTS EISAI'S APPLICATION SEEKING ADDITIONAL INDICATION OF SEVERE ALZHEIMER'S DISEASE FOR ARICEPT®
2015-03-02EISAI LAUNCHES ANTICANCER AGENT LENVIMA™ IN THE UNITED STATESFIRST COUNTRY IN THE WORLD TO GAIN ACCESS TO NEW TREATMENT ...
2015-02-25EISAI TO ESTABLISH ORAL SOLID DOSE PRODUCTION FACILITY AT NEW SUZHOU PLANT IN CHINA
2015-02-25PHASE III TRIAL OF ANTICANCER AGENT HALAVEN® IN SOFT TISSUE SARCOMA SHOWS OVERALL SURVIVAL BENEFIT IN PRIMARY ENDPOINT
2015-02-24ADDITIONAL EXPLORATORY ANALYSIS OF PHASE II TRIAL SUGGESTS ANTICANCER AGENT LENVATINIB EXTENDS OVERALL SURVIVAL IN PATIE...
2015-02-24EISAI LAUNCHES PROTON PUMP INHIBITOR PARIET® TABLETS 5 MG IN JAPAN
2015-02-19EISAI RECEIVES APPROVAL IN JAPAN FOR FINE GRANULE FORMULATION OF ANTI-ARRHYTHMIC AGENT TAMBOCOR® SUITABLE FOR PEDIATRIC ...
2015-02-16U.S. FDA APPROVES ANTICANCER AGENT LENVIMA™ (LENVATINIB MESYLATE) AS TREATMENT FOR RADIOACTIVE IODINE-REFRACTORY DIFFERE...
2015-02-16EISAI RECEIVES APPROVAL OF ANTIEPILEPTIC DRUG BANZEL® (RUFINAMIDE) AS ADJUNCTIVE TREATMENT FOR PEDIATRIC PATIENTS IN THE...
2015-02-12ANTICANCER AGENT LENVATINIB PHASE III TRIAL RESULTS PUBLISHED IN NEW ENGLAND JOURNAL OF MEDICINESIGNIFICANT IMPROVEMENT ...
2015-02-05NOTICE REGARDING EISAI'S OPTIONS RELATING TO BIOGEN IDEC'S INVESTIGATIONAL ANTI-ALZHEIMER'S DISEASE TREATMENTS
1970-01-01Vernalis plc and Servier enter into a new drug discovery collaboration strengthening their existing partnership.
1970-01-01Mundipharma announces results of pivotal phase III study for \u003cstrong\u003e\u003cem\u003eflutiform\u003c/em\u003e\u0... (PDF)
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.